



Semmelweis Egyetem
KARDIOLÓGIAI
KÖZPONT

Cardiac Center, Radiology Unit

Clinical Cardiovascular
Physiology




Magnetic resonance

- History
 - Steady-state free precession in nuclear magnetic resonance
 - **Phys Rev 112(5):1693-1701 (1958)**, HY Carr
 - Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients
 - **Am J Roentgenol 143(2):215-227 (1984)**
 - Magnetic resonance imaging of the heart: a review of experience in 172 subjects
 - **Radiology 155(3):671-679 (1985)**, CB Higgins

Magnetic resonance

- No ionizing radiation
- Superb CNR
- Accurate
- Flow quantification
- Time consuming
- Monitoring
- Requires cooperation
- Complicated


Long axis




Constant volume theorem

- The volume of the pericardial sac remains nearly constant over the cardiac cycle
 - It deviates less than 5% from the equilibrium
 - Prof Kovács J Sándor
 - **AJP Heart Circ Physiol 285(5):H2027 (2003)**
 - <http://cbl1.wustl.edu>







LV evaluation




Right ventricular evaluation









Female water-polo player




LV EDV index – females



Male kayaker



Left ventricular mass index – males



Male normal values

Parameter	Volunteers (48)	Water-polo (N = 23)	Kayak (N = 21)	Canoe (N = 15)	Cycling (N = 9)	Ultra running (N = 5)	Rowing (N = 15)	Goalball (N = 6)
BSA (m ²)	2.04 ± 0.18	2.33 ± 0.09	2.08 ± 0.13	2.00 ± 0.08	1.87 ± 0.10	1.82 ± 0.08	2.00 ± 0.11	2.13 ± 0.19
LVEF	60.2 ± 5.3	57.0 ± 3.4	57.7 ± 4.8	56.9 ± 3.4	56.8 ± 3.5	58.1 ± 3.5	56.2 ± 4.0	58.7 ± 4.4
LVESVi	38.1 ± 8.3	53.0 ± 8.0	52.2 ± 10.5	56.5 ± 8.7	54.3 ± 5.9	46.9 ± 2.8	54.8 ± 9.2	41.6 ± 8.0
LVEDVi	95.2 ± 12.1	123.0 ± 13.3	122.5 ± 14.7	131.0 ± 14.6	125.3 ± 6.4	112.1 ± 5.0	124.5 ± 12.5	99.8 ± 12.2
LVSVi	57.1 ± 7.0	70.0 ± 7.8	70.3 ± 7.6	74.5 ± 8.2	71.1 ± 4.8	65.2 ± 6.3	69.6 ± 5.9	58.3 ± 6.0
LVMi	63.5 ± 10.3	86.4 ± 14.7	95.7 ± 11.1	102.2 ± 13.4	78.1 ± 15.4	79.5 ± 9.7	90.2 ± 9.0	62.6 ± 7.2
RVEF	59.1 ± 4.8	56.2 ± 4.4	55.7 ± 4.3	53.6 ± 3.9	55.1 ± 4.8	57.9 ± 3.0	54.6 ± 3.9	57.1 ± 1.2
RVESVi	40.1 ± 8.3	56.3 ± 11.6	58.1 ± 11.6	64.3 ± 8.9	60.1 ± 10.1	51.4 ± 10.5	59.8 ± 9.4	42.1 ± 5.2
RVEDVi	97.5 ± 13.2	127.7 ± 17.4	130.4 ± 16.7	138.5 ± 14.4	133.3 ± 9.6	122.1 ± 10.5	131.0 ± 12.9	98.3 ± 12.7
RVSVi	57.4 ± 7.7	71.4 ± 8.5	72.3 ± 7.8	74.2 ± 9.0	73.2 ± 5.3	70.7 ± 8.3	71.2 ± 6.2	56.2 ± 7.6
RVMi	24.9 ± 3.6	30.6 ± 3.7	34.2 ± 5.2	34.5 ± 4.9	34.5 ± 4.4	28.2 ± 2.8	33.6 ± 2.7	22.0 ± 2.4
LVED FVS	11.02 ± 1.38	13.17 ± 1.64	13.52 ± 1.91	12.87 ± 1.60	12.00 ± 1.23	12.25 ± 1.26	13.07 ± 1.39	10.50 ± 0.55
Sport index	.118 ± .0246	.107 ± .0149	.112 ± .0231	.099 ± .0181	.096 ± .0122	.109 ± .0119	.106 ± .0150	.106 ± .0115





HCM & DCM example

Parameter	Volunteers	Athletes	DCM	HCM
HR	66,74 (11,24)	59,52 (10,10)	46	53
BSA	2,056 (0,191)	2,046 (0,184)	2,08	2,04
LVEF	59,53 (5,57)	57,51 (4,26)	40,4	63,78
LVESVi	38,72 (8,69)	53,50 (9,63)	112,45	39,99
LVEDVi	95,09 (12,77)	125,25 (13,87)	188,57	110,41
LVSVi	56,37 (7,53)	71,76 (7,21)	76,13	70,42
LVMi	62,93 (11,21)	88,09 (17,66)	125,98	160,90
RVESVi	41,30 (8,10)	59,19 (11,45)	68,52	36,86
RVEDVi	98,37 (13,61)	132,66 (15,40)	144,45	102,08
RVSVi	57,08 (8,33)	73,46 (7,28)	75,94	65,22
RVMi	25,11 (3,97)	34,16 (5,17)	34,30	36,17
ED WT	11,09 (1,46)	12,78 (1,93)	—	29
Sport index	0,119 (0,026)	0,103 (0,021)	—	0,26

DCM example

Parameter	Volunteers	Athletes	DCM	HCM
HR	66,74 (11,24)	59,52 (10,10)	46	53
BSA	2,056 (0,191)	2,046 (0,184)	2,08	2,04
LVEF	59,53 (5,57)	57,51 (4,26)	40,4	63,78
LVESVi	38,72 (8,69)	53,50 (9,63)	112,45	39,99
LVEDVi	95,09 (12,77)	125,25 (13,87)	188,57	110,41
LVSVi	56,37 (7,53)	71,76 (7,21)	76,13	70,42
LVMi	62,93 (11,21)	88,09 (17,66)	125,98	160,90
RVESVi	41,30 (8,10)	59,19 (11,45)	68,52	36,86
RVEDVi	98,37 (13,61)	132,66 (15,40)	144,45	102,08
RVSVi	57,08 (8,33)	73,46 (7,28)	75,94	65,22
RVMi	25,11 (3,97)	34,16 (5,17)	34,30	36,17
ED WT	11,09 (1,46)	12,78 (1,93)	—	29
Sport index	0,119 (0,026)	0,103 (0,021)	—	0,26

Hockey player: dilatative CMP







HCM example

Parameter	Volunteers	Athletes	DCM	HCM
HR	66,74 (11,24)	59,52 (10,10)	46	53
BSA	2,056 (0,191)	2,046 (0,184)	2,08	2,04
LVEF	59,53 (5,57)	57,51 (4,26)	40,4	63,78
LVESVi	38,72 (8,69)	53,50 (9,63)	112,45	39,99
LVEDVi	95,09 (12,77)	125,25 (13,87)	188,57	110,41
LVSVi	56,37 (7,53)	71,76 (7,21)	76,13	70,42
LVMi	62,93 (11,21)	88,09 (17,66)	125,98	160,90
RVESVi	41,30 (8,10)	59,19 (11,45)	68,52	36,86
RVEDVi	98,37 (13,61)	132,66 (15,40)	144,45	102,08
RVSVi	57,08 (8,33)	73,46 (7,28)	75,94	65,22
RVMi	25,11 (3,97)	34,16 (5,17)	34,30	36,17
ED WT	11,09 (1,46)	12,78 (1,93)	—	29
Sport index	0,119 (0,026)	0,103 (0,021)	—	0,26


HCM example

Parameter	Volunteers	Athletes	DCM	HCM
HR	66,74 (11,24)	59,52 (10,10)	46	53
BSA	2,056 (0,191)	2,046 (0,184)	2,08	2,04
LVEF	59,53 (5,57)	57,51 (4,26)	40,4	63,78
LVESVi	38,72 (8,69)	53,50 (9,63)	112,45	39,99
LVEDVi	95,09 (12,77)	125,25 (13,87)	188,57	110,41
LVSVi	56,37 (7,53)	71,76 (7,21)	76,13	70,42
LVMi	62,93 (11,21)	88,09 (17,66)	125,98	160,90
RVESVi	41,30 (8,10)	59,19 (11,45)	68,52	36,86
RVEDVi	98,37 (13,61)	132,66 (15,40)	144,45	102,08
RVSVi	57,08 (8,33)	73,46 (7,28)	75,94	65,22
RVMi	25,11 (3,97)	34,16 (5,17)	34,30	36,17
ED WT	11,09 (1,46)	12,78 (1,93)	—	29
Sport index	0,119 (0,026)	0,103 (0,021)	—	0,26






HCM in an athlete









DE kvantification: 63g scar out of 360g









Muaj thai: Anderson-Fabry (19mm)



Acute infarct: 21% non-viable



Duathlon, ultra-marathon: chrn. infarct





Late/delayed enhancement






- Circulation 104:1101-1107 (2001)
 - Raymond J Kim, Romert M Judd
 - Transmurality ~ Viability









Late/delayed enhancement








RCA & LCX CTO, LMA & LAD stenosis








Apical infarct & thrombus (4CH)








Upslope analysis: MPRI









Inferoseptal stress perfusion problem



Inferoseptal stress perfusion problem



Inducible LAD ischemia



Breathing maneuvers + O₂-sensitive MR

2nd International OS-CMR Symposium

Oxygenation-Sensitive CMR With Breathing Maneuvers for Diagnosing Cardiovascular Disease

A Novel Approach for Assessing Vascular Function

November 19th and 20th, 2021

10:00 – 13:00 EST

[REGISTER HERE - DAY 1](#)

[REGISTER HERE - DAY 2](#)

Centre universitaire
de santé McGill
Institut de recherche




McGill University
Health Centre
Research Institute



GROUPE DE RECHERCHE
RÉSONNANCE
MAGNÉTIQUE
CARDIOVASCULAIRE
COURTOIS
CARDIOVASCULAR
MAGNETIC
RESONANCE
RESEARCH GROUP

Breathing maneuvers + O₂-sensitive MR



Hillier E, and Friedrich MG. Curr Heart Failure Rep 2021

Centre universitaire
de santé McGill
Institut de recherche



GROUPE DE RECHERCHE
RÉSONNANCE
MAGNÉTIQUE
CARDIOVASCULAIRE
COURTOIS
CARDIOVASCULAR
MAGNETIC
RESONANCE
RESEARCH GROUP




Fig 2. Breathing maneuver protocol. For the combined hyperventilation breath-hold (HVBH) maneuver, a single rest measurement was obtained in a short breath-hold (A). The animal was then manually hyperventilated for 60s (B) followed immediately by a long breath-hold (C) that was imaged throughout, with a repeating OS sequence. Hyperventilation analysis was always compared between rest and the start of the breath-hold (red arrow), while the breath-hold could be analyzed at multiple time points with comparison to data obtained at the beginning of the breath-hold (purple arrow). The long breath-hold (LBH) followed step C, starting after a normal ventilation pattern.

doi:10.1371/journal.pone.0164524.g002




Fig 4. Segmental changes of myocardial oxygenation during the HVBH. Subtraction images (smoothed using a 6mm Gaussian filter) demonstrate that at the 30s, SI increased homogeneously in the control animal (A), while there was a decrease in the territory of the stenosed LAD (B). The mean response for each segment from all animals similarly shows that in control animals (top row, n = 8), $\Delta\text{SI}[\%]$ is consistently larger for all segments, whereas for the stenosis animals (bottom row, n = 10) in the LAD regions a significant decrease is already observed at 30s, and this continues throughout the breath-hold. (* $p<0.05$ between LAD and remote territory within the group, † $p<0.05$, <0.05‡ $p<0.01$ for the difference in LAD response between groups).

doi:10.1371/journal.pone.0164524.g004










Fig 5. Myocardial oxygenation response curve during the HVBH. Signal intensity increases globally during the HVBH in control animals (A), yet the animals with a stenosis (B) show a significant decrease in the LAD territory (blue), while the remote region (green) remains above baseline with a similar characteristic of the control animals.







doi:10.1371/journal.pone.0164524.g005

Kawasaki syndrome

Cs: 3D NAV MRCA









Kawasaki, RCA ectasia, stenosis?









Reconstructed tetralogy of Fallot (TOF or FIV)




Axial/transversal cine stack









Long & short axis stack









Functional evaluation








PA 253 16 3, AO 94 2 12, Qp/Qs: 2,27!




J: 106 2 0, B: 146 9 5, R-L: 54-46%




3D NAV MRA









Flow quantification





Flow quantification



VSD





Navigated 3D




3D navigated MRA reconstructions









Further postprocessing








4D flow becoming increasingly popular









Mitral insuff.: 44%, 468cm/s, 88/38Hgmm







FIV, PA Rf: 64%, iNAV MRA, 4D-Flow





CoA, BAV, AOI, Ebstein-, AO Rf: 49%



4D-Flow: Kinetic Energy









2cm/sec

30cm/sec




2cm/sec

30cm/sec



EF=60%
In-plane KE=23%


A




EF=32%
In-plane KE=45%

B


In-house experience





In-house experience




Hemodynamic Forces From 2D - 4D MRI Flow



Arvidsson et al, AJP, 2016



Arvidsson et al. AJP Heart 312(2):H314, 2017



Hemodynamic forces (intra-LV pressure gradients) are normally directed **Base-to-apex** with a highly reproducible pattern with little variability among subjects


What Hemodynamic Forces tell us (Observations)

CONFIRMATIONS BY 4D MR FLOW

NORMAL SUBJECTS

Hemodynamic forces are directed *Base-to-apex*

With highly reproducible pattern





- Ardvissón et al. 2016
- Toger et al. 2018



AMERICAN JOURNAL OF PHYSIOLOGY
Heart and Circulatory
Physiology

PATHOLOGICAL SUBJECTS

Appearance of significant transversal components, alteration of timings, with high variability among subjects




- Ardvissón et al. 2016 AMERICAN JOURNAL OF PHYSIOLOGY Heart and Circulatory Physiology
- Eriksson et al. 2017 SCIENTIFIC REPORTS
- Ardvissón et al. 2018 AMERICAN JOURNAL OF PHYSIOLOGY Heart and Circulatory Physiology

CE-MRA



Flow measurement




Didn't go into details





- Tagging
 - Top Magn Reson Imag 11(6):359-371 (2000)
 - Radiology 214(2):453-466 (2000)
 - J Cardiovasc Magn Reson 4(3):341-351 (2002)
 - J Magn Reson Imag 24(6):1432-1438 (2006)
 - J Magn Reson Imag 29(1):99-105 (2009)

Medis QStrain




Works on SSFP cines
Cutting edge FT-MR
LV, RV and LA

...When you have access to cutting edge, Feature Tracking MR algorithms...





....to obtain a wealth of information with your existing data...

Medis QStrain









Medis QStrain

Left Atrium as well.









n										
terior	-1.062	-0.256	3.006	8.64	15.315	21.743	26.894	30.582	32.73	
eral	0.945	3.648	7.593	12.71	18.944	25.603	31.926	37.919	43.66	
sterior	-3.3	-5.523	-5.773	2.851	2.588	8.053	14.72	19.57	23.4	
erior	-0.264	0.975	1.95	7.081	9.297	9.67	9.034	8.397	8.15	
ptal	0.569	1.149	1.14	0.104	2.106	-4.47	-5.719	-6.244	-6.40	
teroseptal	-1.401	-1.77	-1.913	-2.111	-2.537	-2.694	-3.923	-4.166	-2.20	
	-0.762	-0.297	1.334	3.894	6.883	9.751	11.317	14.596	16.54	
	1.551	3.121	4.589	6.449	9.1	12.313	15.306	17.856	20.00	
rial Strain (Mm)										
terior	-1.501	-3.067	-7.704	-11.307	-16.162	-19.910	-22.276	-25.165	-26.25	
eral	1.341	2.61	2.286	-1.612	-6.388	-11.107	-13.916	-16.484	-18.3	
erior	-1.961	-9.554	-5.01	-9.504	-9.526	-9.956	-11.144	-11.561	-14	
ior	1.395	3.22	2.185	0.75	-0.197	-0.714	-1.557	-4.744	-6.45	
al	-2.033	1.313	-1.115	-3.122	-5.458	-9.263	-11.636	-13.791	-15.02	
roseptal	2.35	0.549	-0.902	4.239	5.071	-6.461	-7.48	-4.294	-10.7	
	-0.061	-0.029	-1.36	4.869	7.267	-9.403	-11.490	-13.675	-15.10	
	1.985	4.813	4.879	4.679	5.295	5.965	6.607	6.931	6.76	







MM: thrombus-, GLS -26%, T2 45ms




MM: thrombus-, GLS -26%, T2 45ms




Anderson-Fabry, QStrain, QMap, LGE-









T1 Mapping and ECV in clinical practice




$$ECV = (1 - \text{haematocrit}) \frac{\frac{1}{\text{post contrast } T1 \text{ myo}} - \frac{1}{\text{native } T1 \text{ myo}}}{\frac{1}{\text{post contrast } T1 \text{ blood}} - \frac{1}{\text{native } T1 \text{ blood}}}$$









Anderson-Fabry: 828/967 ms, 23/33 %




$$ECV = (1 - \text{haematocrit}) \frac{\frac{1}{\text{post contrast } T1 \text{ myo}} - \frac{1}{\text{native } T1 \text{ myo}}}{\frac{1}{\text{post contrast } T1 \text{ blood}} - \frac{1}{\text{native } T1 \text{ blood}}}$$









Amyloidosis – T1: 1166ms, ECV: 65%



$$ECV = (1 - \text{haematocrit}) \frac{\frac{1}{\text{post contrast } T1 \text{ myo}} - \frac{1}{\text{native } T1 \text{ myo}}}{\frac{1}{\text{post contrast } T1 \text{ blood}} - \frac{1}{\text{native } T1 \text{ blood}}}$$




Hemochromatosis: T2* 7ms, liver 1ms



Survival: 71% reduction!

Reduction in cardiac death by 71%





T2* CMR

Modell. J Cardiovasc MR 2008: 42



Didn't go into details

- Magnetic resonance spectroscopy
 - ^1H , ^{31}P , ^{23}Na , ^{13}C
 - MAGMA 11(1-2):44-46 (2000)
 - Heart Lung Circ 12(1):25-30 (2003)
 - Nat Clin Pract Cardiovasc Med 5:S49 (2008)



T2w and FLAIR





ADC and MTT




TOF MRA



Lesion: FLAIR and ADC



Patron saint



Featured literature and links

- Prof Kovács J Sándor
 - <http://www.kardiologia.hu/symposium/73-21334.php>
 - <http://cbl1.wustl.edu>
- MR Physics:
 - Magnetic Resonance Imaging
 - Vlaardingerbroek, ISBN: 3540436812
- Cardiac MRI:
 - Clinical Cardiac MRI
 - Taylor, ISBN: 3540262172

Thanks goes to

- Merkely Béla
- Simor Tamás
- Hüttl Kálmán
- Vágó Hajnalka
- Balázs György
- Referring physicians – GOKI
- <http://atoth.sote.hu/radiol>